Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | METAP2 | P50579 | 2/20 | 0.49 |
| ▸ | METAP1 | P53582 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | CBFB | Q13951 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3432455 | 0.87 | PDE3B (0.50) | KMT2APOLBALDH1A1HPGDUSP2 | |
| SCHEMBL3490546 | 0.84 | KMT2A (0.44) | KMT2APOLBALDH1A1HPGDUSP2 | |
| SCHEMBL266609 | 0.79 | ALDH1A1 (0.66) | KMT2APOLBALDH1A1HPGDUSP2 | |
| SCHEMBL29727934 | 0.79 | ALDH1A1 (0.66) | KMT2APOLBALDH1A1HPGDUSP2 | |
| SCHEMBL1748354 | 0.79 | ALDH1A1 (0.66) | KMT2AALDH1A1HPGDCYP1A2NPC1 | |
| SCHEMBL229608 | 0.76 | KMT2A (0.58) | KMT2APOLBALDH1A1HPGDUSP2 | |
| SCHEMBL1747975 | 0.76 | ALPL (0.56) | ALDH1A1METAP2METAP1CBFB | |
| SCHEMBL9305169 | 0.76 | KMT2A (0.58) | KMT2APOLBALDH1A1HPGDUSP2 | |
| SCHEMBL482021 | 0.76 | ALDH1A1 (0.56) | ALDH1A1HTTRAB9AKDM4EMAPT | |
| SCHEMBL1663312 | 0.76 | MAPT (0.60) | KMT2APOLBALDH1A1HPGDUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070913-A1 | 7-AMINO-3,4-DIHYDROPYRIMIDOPYRIMIDIN-2-ONE DERIVATIVE HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | KOREA INST SCI & TECH (KR) | 2026-03-12 | — | — | US | disclosed |
| US-20230242512-A1 | ISOINDOLINES AS HDAC INHIBITORS | VALO HEALTH, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230103742-A1 | 7-AMINO-3,4-DIHYDROPYRIMIDOPYRIMIDIN-2-ONE DERIVATIVE HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2023-04-06 | — | — | US | disclosed |
| EP-4092029-A1 | 7-AMINO-3,4-DIHYDROPYRIMIDOPYRIMIDIN-2-ONE DERIVATIVE HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | Korea Institute of Science and Technology (KR) | 2022-11-23 | — | — | EP | disclosed |
| US-10174052-B2 | Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-08 | — | — | US | disclosed |
| US-20170305929-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-26 | — | — | US | disclosed |
| EP-3215512-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | Bristol-Myers Squibb Company (US) | 2017-09-13 | — | — | EP | disclosed |
| EP-2291703-B1 | COLOR LIQUID CRYSTAL DISPLAY AND COMPENSATION PANEL | CRYSOPTIX KK (JP) | 2016-11-30 | — | — | EP | disclosed |
| WO-2016073407-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-12 | — | — | WO | disclosed |
| US-8586623-B2 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2013-11-19 | — | — | US | disclosed |
| WO-2009130676-A2 | COLOR LIQUID CRYSTAL DISPLAY AND COMPENSATION PANEL | CRYSOPTIX KK (JP) | 2009-10-29 | — | — | WO | disclosed |
| US-20090268136-A1 | Color Liquid Crystal Display and Compensation Panel | CRYSOPTIX KK (JP) | 2009-10-29 | — | — | US | disclosed |
| WO-2009109782-A2 | POLYCYCLIC ORGANIC COMPOUNDS, RETARDATION LAYER AND COMPENSATION PANEL ON THEIR BASE | CRYSOPTIX K.K. (JP) | 2009-09-11 | — | — | WO | disclosed |
| US-7582761-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20090143575-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | BALAN CHENERA | 2009-06-04 | — | — | US | disclosed |
| WO-2008075109-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| EP-1551811-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | Amgen Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20040152690-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004035549-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | AMGEN INC. (US) | 2004-04-29 | — | — | WO | disclosed |
| US-4000275-A | BENZIMIDAZO(2,1-B) QUINAZOLIN-12(6H)ONES | ELI LILLY AND COMPANY (US) | 1976-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242512-A1 | ISOINDOLINES AS HDAC INHIBITORS | HDAC1, HDAC2, HDAC3 | KMT2A 47/4885POLB 1979/4885ALDH1A1 1133/4885 |
| US-10174052-B2 | Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands | CHRNA7, CHRNA5, CHRNA2 | KMT2A 3214/4885POLB 2940/4885ALDH1A1 846/4885 |
| US-20230103742-A1 | 7-AMINO-3,4-DIHYDROPYRIMIDOPYRIMIDIN-2-ONE DERIVATIVE HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | HASPIN, WEE2, CDK7 | KMT2A 2422/4885POLB 2216/4885ALDH1A1 2732/4885 |
| US-20090143575-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | TRPV1, TRPV3, TRPV2 | KMT2A 3344/4885POLB 2951/4885ALDH1A1 2629/4885 |
| US-20260070913-A1 | 7-AMINO-3,4-DIHYDROPYRIMIDOPYRIMIDIN-2-ONE DERIVATIVE HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | CSNK1A1, CKS1B, HGFAC | KMT2A 3202/4885POLB 2407/4885ALDH1A1 2863/4885 |
| US-20040152690-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | KMT2A 3264/4885POLB 2516/4885ALDH1A1 2522/4885 |
| US-20170305929-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA2 | KMT2A 3419/4885POLB 2537/4885ALDH1A1 824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.